These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10071314)

  • 21. Comparison of colloidal bismuth subcitrate and metronidazole, both in combination with an H2-antagonist as therapy for Helicobacter pylori.
    Baffone W; Belbusti F; Barbieri E; Pianetti A; Bruscolini F; Fabi MT; Salvaggio L; Albano A
    J Chemother; 1997 Jun; 9(3):208-12. PubMed ID: 9210004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects.
    Thijs JC; van Zwet AA; Moolenaar W; Wolfhagen MJ; ten Bokkel Huinink J
    Am J Gastroenterol; 1996 Jan; 91(1):93-7. PubMed ID: 8561152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Helicobacter pylori treatment on rosacea: A single-arm clinical trial study.
    Saleh P; Naghavi-Behzad M; Herizchi H; Mokhtari F; Mirza-Aghazadeh-Attari M; Piri R
    J Dermatol; 2017 Sep; 44(9):1033-1037. PubMed ID: 28452093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of intragastric acidity on Helicobacter pylori eradication with bismuth-metronidazole-amoxicillin.
    Chang CS; Yang CY; Wong FN; Chen GH; Lien HC; Yeh HZ; Poon SK
    Hepatogastroenterology; 1999; 46(28):2713-7. PubMed ID: 10522070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
    Demir M; Göktürk S; Oztürk NA; Serin E; Yilmaz U
    Digestion; 2010; 82(1):47-53. PubMed ID: 20410684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
    Uygun A; Ozel AM; Yildiz O; Aslan M; Yesilova Z; Erdil A; Bagci S; Gunhan O
    J Gastroenterol Hepatol; 2008 Jan; 23(1):42-5. PubMed ID: 17559359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study.
    Onal IK; Gokcan H; Benzer E; Bilir G; Oztas E
    Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):642-6. PubMed ID: 23796974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
    Gungor G; Baglıcakoglu M; Kayacetin E; Biyik M; Ucar R; Goktepe H; Ataseven H; Demir A
    Digestion; 2015; 92(2):55-9. PubMed ID: 26183105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Helicobacter pylori and rosacea.
    Zandi S; Shamsadini S; Zahedi MJ; Hyatbaksh M
    East Mediterr Health J; 2003; 9(1-2):167-71. PubMed ID: 15562747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy with nifuratel to furazolidone.
    Nijevitch AA; Shcherbakov PL; Sataev VU; Khasanov RSh; Al Khashash R; Tuygunov MM
    Aliment Pharmacol Ther; 2005 Nov; 22(9):881-7. PubMed ID: 16225499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies.
    Aktaş B; Başyiğit S; Yüksel O; Akkan T; Atbaşı ST; Uzman M; Yılmaz B; Şimşek G; Nazlıgül Y
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):769-75. PubMed ID: 25919773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
    Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
    Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Helicobacter pylori and its eradication in rosacea.
    Szlachcic A; Sliwowski Z; Karczewska E; Bielański W; Pytko-Polonczyk J; Konturek SJ
    J Physiol Pharmacol; 1999 Dec; 50(5):777-86. PubMed ID: 10695558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study.
    Lerang F; Moum B; Ragnhildstveit E; Haug JB; Hauge T; Tolås P; Aubert E; Henriksen M; Efskind PS; Nicolaysen K; Søberg T; Odegaard A; Berge T
    Am J Gastroenterol; 1997 Apr; 92(4):653-8. PubMed ID: 9128317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
    Srinarong C; Siramolpiwat S; Wongcha-um A; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2014; 15(22):9909-13. PubMed ID: 25520127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized comparison of two rescue therapies for Helicobacter pylori infection.
    Wu DC; Hsu PI; Chen A; Lai KH; Tsay FW; Wu CJ; Lo GH; Wu JY; Wu IC; Wang WM; Tseng HH
    Eur J Clin Invest; 2006 Nov; 36(11):803-9. PubMed ID: 17032348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment.
    Songür Y; Senol A; Balkarli A; Baştürk A; Cerçi S
    Am J Med Sci; 2009 Jul; 338(1):50-3. PubMed ID: 19474657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.